X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Cellbox Solutions Appoints Dr. Herbert Mueller-Hartmann as Head of Research and Development

Content Team by Content Team
8th June 2020
in News
Cellbox Solutions Appoints Dr. Herbert Mueller-Hartmann as Head of Research and Development

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Cellbox Solutions GmbH announces the appointment of former Head of Biosolutions R&D from Lonza Pharma and Biotech, Dr. Herbert A. Mueller-Hartmann, as the new Head of Research and Development. Dr. Mueller-Hartmann will be continuing on the successful work of Dr. Hans-Otto Nagels.

Wolfgang Kintzel, CEO of Cellbox Solutions, commented: “As Cellbox Solutions enters into its next phase of growth, it is with great pleasure that we announce Herbert as our new Head of R&D. Herbert brings with him extensive experience and a strong record for developing significant new technologies from his time as the Global Head of Biosolutions R&D at Lonza AG.”

“Herbert will play a pivotal role in driving our R&D strategy to further grow our pipeline. His experience will be valuable in building an excellent product portfolio, both in the field of new live cell shipment devices and relevant solutions for packaging and storing biological material,” added Prof. Dr. Kathrin Adlkofer, COO and founder of Cellbox Solutions.

“I am honoured to join the Cellbox team in this important role. Cellbox Solutions is a young and ambitious company with talented scientists who aim to revolutionise the cell therapy sector,” stated Dr. Mueller-Hartmann.

Prior to joining Cellbox Solutions, Dr. Mueller-Hartmann was the Global Head of Biosolutions R&D and Head of Research & Technology Bioscience at Lonza Pharma and Biotech. Here he gained experience in the fields of cell and media product development, including applications for the cell & gene therapy market. He will work closely with the Business Development team, where his previous work in innovation management for the Lonza Bioscience business unit will be highly advantageous. Having managed the complete development process from idea generation to its launch, of consumables, hardware and software, his previous experience will be invaluable for enhancing Cellbox’s solution-oriented product portfolio.

Herbert holds a PhD in Biology from the University of Cologne and a certification as Chief Technology Manager from RWTH International Academy in Aachen.

Cellbox Solutions’ strategic path for 2020/2021 is defined by a focus on strong international expansion efforts and the commercial launch of Cellbox’s expanded product portfolio. Under the new leadership, priority will be given to global cooperation to address sales, product innovation and corporate growth.

About Cellbox Solutions
Cellbox Solutions GmbH, founded in 2016, is a spin-off from the Fraunhofer Research Institution for Marine Biotechnology and Cell Technology in Lübeck focusing on innovative logistic solutions for the global BioMedTech industry. Our portable CO2 incubator, the Cellbox®, provides a controlled environment for the transport of living cells and biological structures, where temperature and CO2 can be adjusted to ensure optimal incubation conditions. We have the vision of transforming the future of healthcare by providing support for new treatments that foster the focus from treating to healing. Our aim is to provide cell logistic solutions that facilitate life enabling therapy designs and to make them accessible for everybody.

Previous Post

Lonza to Host New Webinar – “The Compendia are ready. Are you? A More Sustainable Future for Endotoxin Testing”

Next Post

UCB Acquires Engage Therapeutics for $125M

Related Posts

FDA Accepts BLA for Recommended
FDA Approvals

FDA Accepts BLA for Recommended Biosimilar to Simponi

22nd July 2025
Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
Next Post
UCB Acquires Engage Therapeutics for $125M

UCB Acquires Engage Therapeutics for $125M

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In